{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T13:44:54Z","timestamp":1776001494626,"version":"3.50.1"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373183"],"award-info":[{"award-number":["82373183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104968","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:08:35Z","timestamp":1758773315000},"page":"104968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Protein post-translational modifications in CAR-T cells: Novel strategies to amplify antitumor efficacy via epigenetic and metabolic circuitry"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0017-8558","authenticated-orcid":false,"given":"Jiayi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-RW2022-017","article-title":"CAR T-cell efficacy in solid tumors is affected by N-glycosylation","volume":"12","author":"ANON","year":"2022","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/1535-7163.MCT-23-0221","article-title":"Targeting solid cancers with a Cancer-Specific monoclonal antibody to surface expressed aberrantly O-glycosylated proteins","volume":"22","author":"Aasted","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib3","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1038\/s41467-024-54794-x","article-title":"Cullin-5 deficiency promotes chimeric antigen receptor t cell effector functions potentially via the modulation of JAK\/STAT signaling pathway","volume":"15","author":"Adachi","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/ijmm.2017.3036","article-title":"The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)","volume":"40","author":"Ardito","year":"2017","journal-title":"Int J. Mol. Med."},{"issue":"31","key":"10.1016\/j.critrevonc.2025.104968_bib5","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained Progression-Free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-Term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib7","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.124.321164","article-title":"Rictor, an mTORC2 protein, regulates murine lymphatic valve formation through the AKT-FOXO1 signaling","volume":"44","author":"Banerjee","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.critrevonc.2025.104968_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105502","article-title":"Histone lactylation in macrophage biology and disease: from plasticity regulation to therapeutic implications","volume":"111","author":"Bao","year":"2025","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/15548627.2021.1988357","article-title":"GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions","volume":"18","author":"Brun","year":"2022","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202100265","article-title":"In-depth analysis of proteomic and genomic fluctuations during the time course of human embryonic stem cells directed differentiation into beta cells","volume":"22","author":"Budnik","year":"2022","journal-title":"Proteomics"},{"key":"10.1016\/j.critrevonc.2025.104968_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107544","article-title":"Targeting protein-protein interactions in drug discovery: modulators approved or in clinical trials for cancer treatment","volume":"211","author":"Camps-Fajol","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2025.104968_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176841","article-title":"The role of novel protein acylations in cancer","volume":"979","author":"Cao","year":"2024","journal-title":"Eur. J. Pharm."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104968_bib13","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","article-title":"Recent progress in histone deacetylase inhibitors as anticancer agents","volume":"27","author":"Cappellacci","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.immuni.2020.07.023","article-title":"Preventing ubiquitination improves CAR t cell therapy via 'CAR Merry-Go-Around","volume":"53","author":"Chapman","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41392-020-0196-9","article-title":"Regulating tumor suppressor genes: post-translational modifications","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104968_bib16","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1093\/emboj\/cdf660","article-title":"Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB","volume":"21","author":"Chen","year":"2002","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cmet.2023.04.017","article-title":"Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8(+) t cells in the tumor microenvironment","volume":"35","author":"Cheng","year":"2023","journal-title":"Cell Metab."},{"issue":"52","key":"10.1016\/j.critrevonc.2025.104968_bib18","doi-asserted-by":"crossref","first-page":"20135","DOI":"10.1074\/jbc.RA119.009093","article-title":"Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments","volume":"294","author":"Contreras-Baeza","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104968_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70376","volume":"13","author":"Cramer","year":"2024","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002371","article-title":"Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor","volume":"9","author":"Curti","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104968_bib21","article-title":"Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104968_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood.2021010721","article-title":"Phase 1\/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia","volume":"139","author":"Deangelo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104968_bib23","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/1078-0432.CCR-13-2459","article-title":"A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes","volume":"20","author":"Demotte","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nsmb.1842","article-title":"Post-translational modifications in signal integration","volume":"17","author":"Deribe","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s13402-023-00770-4","article-title":"Aberrant N-glycosylation in cancer: MGAT5 and beta1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression","volume":"46","author":"De-Souza-Ferreira","year":"2023","journal-title":"Cell Oncol. (Dordr)"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40265-020-01464-z","article-title":"Lonafarnib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104968_bib30","article-title":"Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104968_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41423-024-01198-y","article-title":"4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20","volume":"21","author":"Dou","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.chembiol.2023.03.006","article-title":"Phosphorylation barcodes direct biased chemokine signaling at CXCR3","volume":"30","author":"Eiger","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/med.21364","article-title":"Mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104968_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ph16121635","article-title":"Comparative assessment and High-Throughput Drug-Combination profiling of TEAD-Palmitoylation inhibitors in hippo pathway deficient mesothelioma","volume":"16","author":"Evsen","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib35","article-title":"A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large b cell lymphoma","volume":"3","author":"Fahrmann","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2025.104968_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106701","article-title":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","volume":"189","author":"Fang","year":"2023","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104968_bib38","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood.2019001751","article-title":"Lenalidomide in follicular lymphoma","volume":"135","author":"Flowers","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib39","first-page":"391","article-title":"Advances in targeted therapy for malignant pleural mesothelioma","volume":"27","author":"Fu","year":"2024","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/1535-7163.MCT-24-0307","article-title":"Zelenirstat inhibits N-Myristoyltransferases to disrupt src family kinase signaling and oxidative phosphorylation, killing acute myeloid leukemia cells","volume":"24","author":"Gamma","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat. Cell Biol."},{"issue":"10166","key":"10.1016\/j.critrevonc.2025.104968_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104968_bib43","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1182\/blood-2018-99-116019","article-title":"Combining De-Glycosylating agents with CAR-T cells for targeting solid tumors and reducing toxicity","volume":"132","author":"Greco","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1021\/acs.jproteome.1c00735","article-title":"SILAC phosphoproteomics reveals unique signaling circuits in CAR-T cells and the inhibition of b Cell-Activating phosphorylation in target cells","volume":"21","author":"Griffith","year":"2022","journal-title":"J. Proteome Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molonc.2010.09.004","article-title":"Phosphoproteomics in cancer","volume":"4","author":"Harsha","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104968_bib47","first-page":"95","article-title":"Armored CAR T-Cells: the next chapter in T-Cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.critrevonc.2025.104968_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejpb.2016.01.005","article-title":"N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and fc fusion proteins","volume":"100","author":"Higel","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1432-1033.2004.04404.x","article-title":"Principles behind the multifarious control of signal transduction. Erk phosphorylation and kinase\/phosphatase control","volume":"272","author":"Hornberg","year":"2005","journal-title":"FEBS J."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib50","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","article-title":"IL-13Ralpha2\/TGF-beta bispecific CAR-T cells counter TGF-beta-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib52","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2025.104968_bib53","article-title":"Lactate-mediated lactylation in human health and diseases: progress and remaining challenges","author":"Hu","year":"2024","journal-title":"J. Adv. Res"},{"key":"10.1016\/j.critrevonc.2025.104968_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101082","article-title":"Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies","volume":"74","author":"Huang","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004560","article-title":"The structural basis for activation and inhibition of ZAP-70 kinase domain","volume":"11","author":"Huber","year":"2015","journal-title":"PLoS Comput. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib56","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.molcel.2021.01.014","article-title":"A comprehensive phenotypic CRISPR-Cas9 screen of the ubiquitin pathway uncovers roles of ubiquitin ligases in mitosis","volume":"81","author":"Hundley","year":"2021","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","article-title":"Romidepsin for the treatment of peripheral T-Cell lymphoma","volume":"20","author":"Iyer","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib58","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of SUV39H1-Mediated H3K9 methylation sustains CAR T-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov."},{"issue":"D1","key":"10.1016\/j.critrevonc.2025.104968_bib59","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-024-00589-7","article-title":"The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma","volume":"12","author":"Jiang","year":"2024","journal-title":"Biomark. Res."},{"issue":"6718","key":"10.1016\/j.critrevonc.2025.104968_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4492","article-title":"Epigenetic regulators of clonal hematopoiesis control CD8 t cell stemness during immunotherapy","volume":"386","author":"Kang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104968_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR t cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2025.104968_bib63","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429249717230920113227","article-title":"Regulating miRNAs expression by resveratrol: novel insights based on molecular mechanism and strategies for cancer therapy","volume":"17","author":"Keshavarzmotamed","year":"2023","journal-title":"Curr. Mol. Pharm."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104968_bib64","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1073\/pnas.85.16.5849","article-title":"Specific dephosphorylation of phosphoproteins by protein-serine and -tyrosine kinases","volume":"85","author":"Kole","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1039\/D1MD00386K","article-title":"Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors","volume":"13","author":"Kong","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.104968_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217156","article-title":"Glycolysis, the sweet appetite of the tumor microenvironment","volume":"600","author":"Kooshan","year":"2024","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib67","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","article-title":"Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model","volume":"71","author":"Kumar","year":"2022","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030819","article-title":"Regulation of T-Cell signaling by Post-Translational modifications in autoimmune disease","volume":"19","author":"Kuwabara","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104968_bib69","article-title":"YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of t cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity","volume":"13","author":"Lam","year":"2022","journal-title":"Front. Pharm."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib70","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.chembiol.2023.10.024","article-title":"Genetic retargeting of E3 ligases to enhance CAR t cell therapy","volume":"31","author":"Lane","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"5040","key":"10.1016\/j.critrevonc.2025.104968_bib72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.1532456","article-title":"Activation of t cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon","volume":"255","author":"Letourneur","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib73","first-page":"62","article-title":"Breaking boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Med. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib74","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ccell.2024.09.006","article-title":"Lactylation in cancer: current understanding and challenges","volume":"42","author":"Li","year":"2024","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104968_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215307","article-title":"Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with Non-Small cell lung cancer carrying uncommon EGFR mutations: a comparative cohort study in China (AFANDA Study)","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104968_bib76","article-title":"The dual role of exosomes in the tumor microenvironment: from Pro-Tumorigenic signaling to immune modulation","author":"Li","year":"2025","journal-title":"Med. Res."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2025.104968_bib77","article-title":"Targeting metabolic pathway enhance CAR-T potency for solid tumor","volume":"143","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib78","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41392-021-00825-8","article-title":"Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib79","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","article-title":"Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy","volume":"53","author":"Li","year":"2020","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104968_bib80","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2174\/0109298665245603231106050224","article-title":"Unleashing breast cancer progression: miR-455-5p's targeting of SOCS3 drives proliferation, migration, and invasion","volume":"30","author":"Li","year":"2023","journal-title":"Protein Pept. Lett."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050851","article-title":"Ubiquitination-Proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib82","article-title":"CD73, a promising therapeutic target of diclofenac, promotes metastasis of pancreatic cancer through a nucleotidase independent mechanism","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cpan.2024.12.002","article-title":"Advances in drug discovery based on network pharmacology and omics technology","volume":"21","author":"Liu","year":"2024","journal-title":"Curr. Pharm. Anal."},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104968_bib84","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as First-Line therapy for locally advanced or MetastaticNon-Small-Cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104968_bib85","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2174\/0929866530666230526143710","article-title":"Research progress of BAP1 in structure, function, and cancer","volume":"30","author":"Lu","year":"2023","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.critrevonc.2025.104968_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","article-title":"Disruption of CISH promotes the antitumor activity of human t cells and decreases PD-1 expression levels","volume":"28","author":"Lv","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib87","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2011.04.025","article-title":"Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth","volume":"42","author":"Lv","year":"2011","journal-title":"Mol. Cell"},{"issue":"7786","key":"10.1016\/j.critrevonc.2025.104968_bib88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR t cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib89","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","article-title":"Cellular metabolism regulates the differentiation and function of T-cell subsets","volume":"21","author":"Ma","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104968_bib90","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","article-title":"Mobocertinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104968_bib91","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1200\/EDBK_280571","article-title":"Biomarkers in precision cancer immunotherapy: promise and challenges","author":"Mckean","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005891","article-title":"Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma","volume":"11","author":"Mckenna","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s42003-020-0819-2","article-title":"Development of smart anti-glycan reagents using immunized lampreys","volume":"3","author":"Mckitrick","year":"2020","journal-title":"Commun. Biol."},{"issue":"499","key":"10.1016\/j.critrevonc.2025.104968_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR t cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"499","key":"10.1016\/j.critrevonc.2025.104968_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR t cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"48","key":"10.1016\/j.critrevonc.2025.104968_bib96","doi-asserted-by":"crossref","first-page":"18465","DOI":"10.1074\/jbc.RA119.011134","article-title":"Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding","volume":"294","author":"Mondal","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi6696","article-title":"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases","volume":"8","author":"Moreno-Yruela","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/biom11010015","article-title":"Phosphorylation of the regulators, a complex facet of NF-kappaB signaling in cancer","volume":"11","author":"Motolani","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2025.104968_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11932","article-title":"Activation of STING requires palmitoylation at the Golgi","volume":"7","author":"Mukai","year":"2016","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104968_bib100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm.2017.35","article-title":"The winding path of protein methylation research: milestones and new frontiers","volume":"18","author":"Murn","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib101","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/jm501061a","article-title":"Inhibiting the deubiquitinating enzymes (DUBs)","volume":"58","author":"Ndubaku","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.104968_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116699","article-title":"Exosomes as carriers to stimulate an anti-cancer immune response in immunotherapy and as predictive markers","volume":"232","author":"Nie","year":"2025","journal-title":"Biochem Pharm."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-Mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib104","article-title":"A phase I study of unimolecular pentavalent (Globo-H-GM2-sTn-TF-Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission","volume":"8","author":"O'Cearbhaill","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104968_bib105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41388-020-01586-4","article-title":"TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia","volume":"40","author":"Ochiiwa","year":"2021","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104968_bib106","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104968_bib107","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.acr.2019.03.003","article-title":"Co-stimulatory and co-inhibitory pathways in cancer immunotherapy","volume":"143","author":"O'Neill","year":"2019","journal-title":"Adv. Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104968_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167829","article-title":"TSC2 S1365A mutation potently regulates CD8+ t cell function and differentiation and improves adoptive cellular cancer therapy","volume":"8","author":"Patel","year":"2023","journal-title":"JCI Insight"},{"issue":"6316","key":"10.1016\/j.critrevonc.2025.104968_bib109","first-page":"1160","article-title":"Epigenetic stability of exhausted t cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science (American Association Advancement Science)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1600-065X.2009.00763.x","article-title":"Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections","volume":"229","author":"Pentcheva-Hoang","year":"2009","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib111","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdy336","article-title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","volume":"29","author":"Piotrowska","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib112","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR t cells targeting the Cancer-Associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib113","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104968_bib115","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs Piperacillin-Tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrm.2017.83","article-title":"Ubiquitylation at the crossroads of development and disease","volume":"19","author":"Rape","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib117","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41467-017-02763-y","article-title":"T cells specific for post-translational modifications escape intrathymic tolerance induction","volume":"9","author":"Raposo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104968_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103580","article-title":"Development of asciminib, a novel allosteric inhibitor of BCR-ABL1","volume":"171","author":"Rea","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"_1","key":"10.1016\/j.critrevonc.2025.104968_bib119","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib120","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib121","article-title":"Bortezomib for the treatment of multiple myeloma","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst. Rev. 4"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104968_bib122","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2(A)R and A2(B)R dual antagonist AB928\/etrumadenant on CAR t cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104968_bib123","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429310703240823045808","article-title":"Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation","volume":"17","author":"Sensi","year":"2024","journal-title":"Curr. Mol. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib124","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41392-022-01245-y","article-title":"Protein acylation: mechanisms, biological functions and therapeutic targets","volume":"7","author":"Shang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib125","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/JTO.0b013e31825134ac","article-title":"Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases","volume":"7","author":"Sharma","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104968_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.639666","article-title":"Glycosaminoglycan-Protein interactions and their roles in human disease","volume":"8","author":"Shi","year":"2021","journal-title":"Front Mol. Biosci."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104968_bib127","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-018-1028-x","article-title":"Dacomitinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","article-title":"Mitochondrial isocitrate dehydrogenase impedes CAR t cell function by restraining antioxidant metabolism and histone acetylation","volume":"36","author":"Si","year":"2024","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74003-5","article-title":"Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment","volume":"14","author":"Soh","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104968_bib131","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-23-3023","article-title":"Negative hyperselection of resistance mutations for panitumumab maintenance in RAS Wild-Type metastatic colorectal cancer (Panama Phase II Trial, AIO KRK 0212)","volume":"30","author":"Stahler","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091313","article-title":"Glycosylation-The most diverse Post-Translational modification","volume":"12","author":"Staudacher","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib133","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13046-023-02815-w","article-title":"Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation","volume":"42","author":"Sun","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib134","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/cr.2016.39","article-title":"Ubiquitin modifications","volume":"26","author":"Swatek","year":"2016","journal-title":"Cell Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-02-207118","article-title":"Regulation of treg functionality by acetylation-mediated Foxp3 protein stabilization","volume":"115","author":"van Loosdregt","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104968_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/stke.119pe21","article-title":"TCR triggering by the pMHC complex: valency, affinity, and dynamics","volume":"1","author":"Varma","year":"2008","journal-title":"Sci. Signal"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1021\/acscentsci.5b00345","article-title":"Antroquinonol A: scalable synthesis and preclinical biology of a phase 2 drug candidate","volume":"2","author":"Villaume","year":"2016","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib138","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1038\/s41467-024-52507-y","article-title":"PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma","volume":"15","author":"Walton","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib139","article-title":"CAR-T cell therapy for hematological malignancies: history, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jcmm.13920","article-title":"CPT1A-mediated succinylation of S100A10 increases human gastric cancer invasion","volume":"23","author":"Wang","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114686","article-title":"H3K9 lactylation in malignant cells facilitates CD8(+) t cell dysfunction and poor immunotherapy response","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104968_bib142","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"issue":"7684","key":"10.1016\/j.critrevonc.2025.104968_bib143","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature25003","article-title":"KAT2A coupled with the alpha-KGDH complex acts as a histone H3 succinyltransferase","volume":"552","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104968_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104968_bib145","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104968_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-gamma response in NK-T cell lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib147","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2022.03.013","article-title":"The mitochondrial pyruvate carrier regulates memory t cell differentiation and antitumor function","volume":"34","author":"Wenes","year":"2022","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104968_bib148","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103637","article-title":"PTPN2 phosphatase deletion in t cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours","volume":"39","author":"Wiede","year":"2020","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib149","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","article-title":"Extensive remodeling of the immune microenvironment in b cell acute lymphoblastic leukemia","volume":"37","author":"Witkowski","year":"2020","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104968_bib150","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers16162858","article-title":"Strategies for improving CAR t cell persistence in solid tumors","volume":"16","author":"Wittling","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104968_bib151","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","article-title":"Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas","volume":"118","author":"Witzig","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib152","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.ymthe.2023.09.017","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVDelta51 oncolytic virotherapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib153","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s10637-019-00864-7","article-title":"Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma","volume":"38","author":"Wood","year":"2020","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2025.104968_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103194","article-title":"Histone lactylation-regulated METTL3 promotes ferroptosis via m6A-modification on ACSL4 in sepsis-associated lung injury","volume":"74","author":"Wu","year":"2024","journal-title":"Redox Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104968_bib155","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107453119","article-title":"O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib156","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3epsilon and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib157","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12943-023-01856-1","article-title":"CircXRN2 suppresses tumor progression driven by histone lactylation through activating the hippo pathway in human bladder cancer","volume":"22","author":"Xie","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104968_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106739","article-title":"beta-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer","volume":"191","author":"Xu","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2025.104968_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116331","article-title":"Comprehensive review of histone lactylation: structure, function, and therapeutic targets","volume":"225","author":"Xu","year":"2024","journal-title":"Biochem. Pharm."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cac2.12610","article-title":"Altered glycosylation in cancer: molecular functions and therapeutic potential","volume":"44","author":"Xu","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104968_bib161","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"37","key":"10.1016\/j.critrevonc.2025.104968_bib162","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","article-title":"HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention","volume":"26","author":"Yang","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib163","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104968_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38426","article-title":"Lactate and lysine lactylation of histone regulate transcription in cancer","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-018-0814-0","article-title":"Engineering chimeric antigen receptor-T cells for cancer treatment","volume":"17","author":"Ye","year":"2018","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104968_bib166","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","article-title":"A genome-scale gain-of-function CRISPR screen in CD8 t cells identifies proline metabolism as a means to enhance CAR-T therapy","volume":"34","author":"Ye","year":"2022","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib167","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41421-021-00255-4","article-title":"CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy","volume":"7","author":"Yi","year":"2021","journal-title":"Cell Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104968_bib168","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055014","article-title":"Role of ganetespib, an HSP90 inhibitor, in cancer therapy: from molecular mechanisms to clinical practice","volume":"24","author":"Youssef","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104968_bib169","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/med.21437","article-title":"The search for potent, Small-Molecule HDACIs in cancer treatment: a decade after vorinostat","volume":"37","author":"Zagni","year":"2017","journal-title":"Med. Res. Rev."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104968_bib170","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-23-3513","article-title":"H3K18 lactylation potentiates immune escape of non-small cell lung cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104968_bib171","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib172","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41418-022-01012-0","article-title":"Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer","volume":"29","author":"Zhang","year":"2022","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104968_bib173","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1021\/acs.jmedchem.3c01845","article-title":"Series of desloratadine Platinum(IV) hybrids displaying potent antimetastatic competence by inhibiting Epithelial-Mesenchymal transition and arousing immune response","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"101","key":"10.1016\/j.critrevonc.2025.104968_bib174","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp7302","article-title":"Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity","volume":"9","author":"Zhang","year":"2024","journal-title":"Sci. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104968_bib175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215732120","article-title":"Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target","volume":"120","author":"Zhou","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.104968_bib176","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR t cells targeting the tumor MUC1 glycoprotein reduce Triple-Negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104968_bib177","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s11010-024-05040-x","article-title":"Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers","volume":"479","author":"Zhu","year":"2024","journal-title":"Mol. Cell Biochem."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:07:29Z","timestamp":1773126449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":177,"alternative-id":["S1040842825003567"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104968","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein post-translational modifications in CAR-T cells: Novel strategies to amplify antitumor efficacy via epigenetic and metabolic circuitry","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104968"}}